Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Ibrahim, Toni ^a   Mercatali, Laura ^a   Sacanna, Emanuele ^a   Tesei, Anna ^a   Carloni, Silvia ^a   Ulivi, Paola ^a   Liverani, Chiara ^a   Fabbri, Francesco ^a   Zanoni, Michele ^a   Zoli, Wainer ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Bone metastasis; Breast cancer; Cell lines; Zoledronic acid

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SULFORHODAMINE B; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; OSTEOCLAST; PROTEIN EXPRESSION; REPEATED DRUG DOSE; WESTERN BLOTTING;

EID: 84869882226     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-48     Document Type: Article

References (57)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12(20 Pt 2):6243s-6249s.
3. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANK-L. Int J Oncol 2011, 39(1):255-261.
4. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology 2011, 80(3-4):225-231.
5. Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 2000, 7(4):271-284. 10.1677/erc.0.0070271, 11174848.
6. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. Tumori 2009, 95(3):291-297.
7. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176. 10.1053/ctrv.2000.0210, 11417967.
8. Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007, 46(2):221-229. 10.1080/02841860600635870, 17453373.
9. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116(6):1406-1418. 10.1002/cncr.24896, 20108337.
10. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(12 Suppl):2961-2978.
11. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113(1):193-201. 10.1002/cncr.23529, 18459173.
12. Doggrell SA. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther 2009, 9(9):1211-1218. 10.1586/era.09.95, 19761424.
13. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 2006, 3(3):143-153. 10.3816/SCT.2006.n.012, 18632488.
14. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 2010, 10(1):46-54. 10.2174/156800910790980223, 20088792.
15. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008, 34(Suppl 1):S19-S24.
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84(8):1126-1134. 10.1054/bjoc.2001.1727, 2363858, 11308265.
17. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996, 98(3):698-705. 10.1172/JCI118841, 507479, 8698861.
18. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60(11):2949-2954.
19. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302(3):1055-1061. 10.1124/jpet.102.035295, 12183663.
20. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003, 9(8):2893-2897.
21. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99(4):322-330. 10.1093/jnci/djk054, 17312309.
22. Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P, Holen I. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008, 14(14):4658-4666. 10.1158/1078-0432.CCR-07-1545, 18628481.
23. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360(7):679-691. 10.1056/NEJMoa0806285, 19213681.
24. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 2010, 36(8):615-620. 10.1016/j.ctrv.2010.04.003, 3047387, 20478658.
25. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009, 9(7):791-800. 10.2174/156800909789760285, 20025567.
26. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010, 11(1):141-154. 10.1517/14656560903485664, 20001436.
27. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822. 10.1056/NEJMoa067312, 17476007.
28. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26(29):4739-4745. 10.1200/JCO.2008.16.4707, 2653138, 18711172.
29. Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G. New developments of aminobisphosphonates: the double face of Janus. Ann Oncol 2007, 18(Suppl 6):vi164-vi167.
30. Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat 2010, 124(3):733-743. 10.1007/s10549-010-1183-6, 20882405.
31. Amadori D, Bertoni L, Flamigni A, Savini S, De Giovanni C, Casanova S, De Paola F, Amadori A, Giulotto E, Zoli W. Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat 1993, 28(3):251-260. 10.1007/BF00666586, 8018954.
32. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112. 10.1093/jnci/82.13.1107, 2359136.
33. Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, Bianco AR, Tagliaferri P. Alpha-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 1995, 61(3):342-347. 10.1002/ijc.2910610312, 7729946.
34. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83(11):757-766. 10.1093/jnci/83.11.757, 2041050.
35. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2010, 5:82. 10.1186/1748-717X-5-82, 2949679, 20849637.
36. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, Caraglia M. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 2007, 14(5):952-962.
37. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009, 125(9):2004-2013. 10.1002/ijc.24648, 19530242.
38. Osborne A. Zoledronic acid. Clin J Oncol Nurs 2002, 6(6):365-366. 10.1188/02.CJON.365-366, 12434471.
39. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113(6):1438-1445. 10.1002/cncr.23775, 2900766, 18720527.
40. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002, 86(9):1479-1486. 10.1038/sj.bjc.6600297, 2375368, 11986784.
41. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhauser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010, 287(1):109-116. 10.1016/j.canlet.2009.06.003, 19577359.
42. Green JR. Bisphosphonates: preclinical review. Oncologist 2004, 9(Suppl 4):3-13.
43. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D, Zoli W. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 2008, 6:43. 10.1186/1479-5876-6-43, 2525627, 18691406.
44. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42(11):1228-1236. 10.1177/009127002762491316, 12412821.
45. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006, 13(1):7-26. 10.1677/erc.1.01094, 16601276.
46. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action, Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88(6):2095-2105. 10.1172/JCI115539, 295810, 1661297.
47. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm 2011, 403(1-2):292-297.
48. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, De Rosa G, Caraglia M. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 2012, 30(1):302-309. 10.1016/j.biotechadv.2011.06.018, 21741464.
49. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011, 7(6):955-964. 10.1016/j.nano.2011.03.004, 21453789.
50. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992, 33(11):1657-1663.
51. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264(1):108-111. 10.1006/bbrc.1999.1499, 10527849.
52. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15(8):1467-1476. 10.1359/jbmr.2000.15.8.1467, 10934645.
53. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82(8):1459-1468. 10.1054/bjoc.1999.1131, 2363380, 10780527.
54. Busch M, Rave-Frank M, Hille A, Duhmke E. Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 1998, 3(9):427-431.
55. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009, 7(4):511-522. 10.1158/1541-7786.MCR-08-0107, 19372580.
56. Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 2008, 15(2):153-158. 10.1007/s12282-008-0034-3, 18311481.
57. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102(7):1099-1105. 10.1038/sj.bjc.6605604, 2853093, 20234364.